Lakefront Biotherapeutics NV (LKFT)

NASDAQ: LKFT · Real-Time Price · USD

28.34

+0.61 (2.20%)

At close: May 28, 2026, 4:00 PM EDT

28.32

-0.02 (-0.07%)

After-hours: May 28, 2026, 4:10 PM EDT

LKFT Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	1,044	1,112	275.65	239.72	241.25	234.38
Revenue	1,044	1,112	275.65	239.72	241.25	234.38
Revenue Growth (YoY)	262.17%	303.50%	14.99%	-0.63%	2.93%	-50.97%
Cost of Revenue	328.44	489.16	370.32	241.29	269.8	320.5
Gross Profit	715.32	623.09	-94.67	-1.57	-28.55	-86.12
Selling, General & Admin	133.01	141.31	133.2	130.82	138.64	131.52
Other Operating Expenses	-47.98	-53.49	-40.77	-47.27	-36.13	-46.07
Operating Expenses	85.03	87.81	92.42	83.54	102.51	85.45
Operating Income	630.28	535.28	-187.1	-85.11	-131.06	-171.57
Interest Expense	-0.39	-1.03	-0.91	-1.77	-6.88	-11.59
Interest & Investment Income	47.24	46.34	89.38	79.29	18.09	2.87
Currency Exchange Gain (Loss)	-45.01	-45.01	22.05	-21.66	44.38	56.66
Other Non Operating Income (Expenses)	96.4	22.63	1	0.13	-2.32	2.39
EBT Excluding Unusual Items	728.52	558.2	-75.58	-29.12	-77.78	-121.25
Merger & Restructuring Charges	-228.11	-228.11	-	-	-	-
Gain (Loss) on Sale of Investments	-17.09	-17.09	73.74	37.9	6.93	1.84
Asset Writedown	-15.28	-15.28	-1.24	-	-	-
Other Unusual Items	3.15	3.15	-	-3.15	-	-
Pretax Income	471.19	300.87	-3.09	5.63	-70.85	-119.4
Income Tax Expense	-16.74	-18.62	-1.8	9.61	0.57	1.39
Earnings From Continuing Operations	487.93	319.49	-1.28	-3.99	-71.42	-120.79
Earnings From Discontinued Operations	0.85	1.39	75.36	215.69	-146.57	17.56
Net Income	488.78	320.88	74.08	211.7	-217.99	-103.23
Net Income to Common	488.78	320.88	74.08	211.7	-217.99	-103.23
Net Income Growth	-	333.15%	-65.01%	-	-	-
Shares Outstanding (Basic)	66	66	66	66	66	66
Shares Outstanding (Diluted)	66	66	66	66	66	66
Shares Change (YoY)	0.03%	-0.06%	0.01%	0.36%	0.30%	0.65%
EPS (Basic)	7.42	4.87	1.12	3.21	-3.32	-1.58
EPS (Diluted)	7.42	4.87	1.12	3.21	-3.32	-1.58
EPS Growth	-	333.66%	-65.05%	-	-	-
Free Cash Flow	-310.33	-271.16	-336.75	-424.68	-527.93	-558.03
Free Cash Flow Per Share	-4.71	-4.12	-5.11	-6.44	-8.04	-8.52
Gross Margin	68.53%	56.02%	-34.34%	-0.66%	-11.83%	-36.74%
Operating Margin	60.39%	48.13%	-67.87%	-35.50%	-54.32%	-73.20%
Profit Margin	46.83%	28.85%	26.88%	88.31%	-90.36%	-44.04%
Free Cash Flow Margin	-29.73%	-24.38%	-122.16%	-177.15%	-218.83%	-238.09%
EBITDA	662.96	568.17	-153.32	-41.47	-65.49	-163.26
EBITDA Margin	63.52%	51.08%	-55.62%	-17.30%	-27.15%	-69.65%
D&A For EBITDA	32.67	32.89	33.78	43.64	65.57	8.31
EBIT	630.28	535.28	-187.1	-85.11	-131.06	-171.57
EBIT Margin	60.39%	48.13%	-67.87%	-35.50%	-54.32%	-73.20%
Effective Tax Rate	-	-	-	170.90%	-	-
Revenue as Reported	1,044	1,112	275.65	239.72	241.25	234.38

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q